DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance.

Schröder M, Renatus M, Liang X, Meili F, Zoller T, Ferrand S, Gauter F, Li X, Sigoillot F, Gleim S, Stachyra TM, Thomas JR, Begue D, Khoshouei M, Lefeuvre P, Andraos-Rey R, Chung B, Ma R, Pinch B, Hofmann A, Schirle M, Schmiedeberg N, Imbach P, Gorses D, Calkins K, Bauer-Probst B, Maschlej M, Niederst M, Maher R, Henault M, Alford J, Ahrne E, Tordella L, Hollingworth G, Thomä NH, Vulpetti A, Radimerski T, Holzer P, Carbonneau S, Thoma CR

Open source

DOI
10.1038/s41467-023-44237-4
Published
2024 Jan 4
Container
Nature communications
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41467-023-44237-4,
  title = {DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance.},
  author = {Schröder M and Renatus M and Liang X and Meili F and Zoller T and Ferrand S and Gauter F and Li X and Sigoillot F and Gleim S and Stachyra TM and Thomas JR and Begue D and Khoshouei M and Lefeuvre P and Andraos-Rey R and Chung B and Ma R and Pinch B and Hofmann A and Schirle M and Schmiedeberg N and Imbach P and Gorses D and Calkins K and Bauer-Probst B and Maschlej M and Niederst M and Maher R and Henault M and Alford J and Ahrne E and Tordella L and Hollingworth G and Thomä NH and Vulpetti A and Radimerski T and Holzer P and Carbonneau S and Thoma CR},
  year = {2024},
  journal = {Nature communications},
  doi = {10.1038/s41467-023-44237-4},
  url = {https://doi.org/10.1038/s41467-023-44237-4}
}

RIS

TY  - JOUR
TI  - DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance.
AU  - Schröder M
AU  - Renatus M
AU  - Liang X
AU  - Meili F
AU  - Zoller T
AU  - Ferrand S
AU  - Gauter F
AU  - Li X
AU  - Sigoillot F
AU  - Gleim S
AU  - Stachyra TM
AU  - Thomas JR
AU  - Begue D
AU  - Khoshouei M
AU  - Lefeuvre P
AU  - Andraos-Rey R
AU  - Chung B
AU  - Ma R
AU  - Pinch B
AU  - Hofmann A
AU  - Schirle M
AU  - Schmiedeberg N
AU  - Imbach P
AU  - Gorses D
AU  - Calkins K
AU  - Bauer-Probst B
AU  - Maschlej M
AU  - Niederst M
AU  - Maher R
AU  - Henault M
AU  - Alford J
AU  - Ahrne E
AU  - Tordella L
AU  - Hollingworth G
AU  - Thomä NH
AU  - Vulpetti A
AU  - Radimerski T
AU  - Holzer P
AU  - Carbonneau S
AU  - Thoma CR
PY  - 2024
JO  - Nature communications
DO  - 10.1038/s41467-023-44237-4
UR  - https://doi.org/10.1038/s41467-023-44237-4
ER  - 

APA

M, S., M, R., X, L., F, M., T, Z., S, F., F, G., X, L., F, S., S, G., TM, S., JR, T., D, B., M, K., P, L., R, A., B, C., R, M., B, P., A, H., M, S., N, S., P, I., D, G., K, C., B, B., M, M., M, N., R, M., M, H., J, A., E, A., L, T., G, H., NH, T., A, V., T, R., P, H., S, C., & CR, T. (2024). DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance.. Nature communications. https://doi.org/10.1038/s41467-023-44237-4

Source records